OPDP

All articles by OPDP

OPDP expands “Bad Ad” with CME
OPDP expands “Bad Ad” with CME
Marc Iskowitz
October 29, 2013
2:11 pm

The agency made good on a pledge to expand Bad Ad with a web-based CME course and case studies representing common problems.

TV interviews trigger Aegerion warning letter
TV interviews trigger Aegerion warning letter
Deborah Weinstein
November 11, 2013
5:57 pm

The FDA’s Bad Ad group says the drugmaker misbranded its cholesterol drug during interviews on CNBC.

Merz web-copy shortcuts don’t sit well with OPDP
Merz web-copy shortcuts don’t sit well with OPDP
Deborah Weinstein
August 7, 2013
5:00 pm

FDA’s Office of Prescription Drug Promotion issued an Untitled Letter over what it says are misleading copy and overstated efficacy claims online.

Business briefs: GlaxoSmithKline and Spectrum
Business briefs: GlaxoSmithKline and Spectrum
August 5, 2013
8:41 pm

GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.

OPDP sends Warning Letter to Acorda
OPDP sends Warning Letter to Acorda
Deborah Weinstein
August 1, 2013
5:23 pm

The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.

Pharma digerati launch advisory firm
Pharma digerati launch advisory firm
Marc Iskowitz
July 17, 2013
8:34 pm

The duo whose nonprofit served as neutral ground for getting FDA and industry talking about digital marketing is starting a for-profit research and advisory firm.

I’ll take DTC for $10 million, Alex
I’ll take DTC for $10 million, Alex
Peter Pitts
July 12, 2013
1:08 pm

The Wizards of White Oak are spending $10 million on DTC ad research. Is this a wise use of sparse agency resources?

Xarelto print ad puts Janssen in hot water
Xarelto print ad puts Janssen in hot water
Deborah Weinstein
July 1, 2013
5:18 pm

The bad-ad group has hit the drug maker with an untitled letter, saying the print piece’s type treatment and other elements mislead patients.

Business briefs: Aveo, Dynavax, Gilead, OPDP
Business briefs: Aveo, Dynavax, Gilead, OPDP
June 10, 2013
6:01 pm

Aveo CRL says company’s kidney drug information is uninterpretable; Dynavax has to find more hepatitis B clinical trial patients; Gilead’s hep C drug gets priority status; OPDP slaps Janssen and Sigma Tau with untitled letters.

Business briefs: Teva, Celgene, Komen, Apple, OPDP
Business briefs: Teva, Celgene, Komen, Apple, OPDP
June 6, 2013
5:47 pm

Plan B age limits retained and rejected, Celgene drugs gets expanded indication, Komen cuts back on walks, Apple is policing medical apps, OPDP director’s Q&A

  • From Our Partners